Professor Fraser, a Fellow of the Royal College of Physicians and Surgeons of Canada, holds a position as Professor and Clinician Scientist in Paediatric Critical Care/Trauma Medicine at Western University in London, Ontario.
He completed his MD/PhD in the Department of Physiology and Biophysics at the University of Calgary, Alberta, receiving a Canadian Institutes of Health Research Strategic Training Fellowship and several esteemed International Research Awards from the American Academy of Pediatrics and the Society for Pediatric Research.
As Director of the Translational Research Centre, a human tissue biobank operating for over 15 years, Professor Fraser has garnered multiple Research Innovation Awards and successfully filed numerous patents. He is also a Co-Founder and Chief Medical Officer of NeuroLytixs, Inc., a diagnostics-based biotech company.
Professor Fraser's research focuses on identifying signalling pathways and diagnostics/prognostic biomarkers for acquired brain injury, severe sepsis and COVID-19. His work includes profiling Long-COVID patients for proteome changes, with particular emphasis on understanding the immune response.
Currently, he leads two International Multicentred Long-COVID Research Programmes: "LC-Optimize" (Identification of Long-COVID Sub-Phenotypes to Optimise Patient Outcomes) and "LC-Statistic" (Sudden Death Associated with Post-COVID Condition).